October 15, 2024

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH

New Member: Welcome in our cluster to Daiichi Sankyo Europe GmbH
Go back

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

Cambridge, UK, and Heidelberg, Germany, 13 April 2026: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows. As part of the collaboration, SPT Labtech’s firefly®+ […]

read more
AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency Berlin, Germany, and Durham, N.C., USA, April 20, 2026 – AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready […]

read more
Molecular signature linked to aggressive growth of head and neck tumors discovered

Molecular signature linked to aggressive growth of head and neck tumors discovered

Researchers from Heidelberg University’s Faculty of Medicine and the Technical University of Munich have investigated the genetic activity of “budding” head and neck carcinomas. In the “buds”—clusters of cells that detach from the tumor and are associated with a poor prognosis—they found a characteristic pattern of gene activity. This marker signature provides insights into the […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp